SCI Pharmtech Investor Relations

SCI Pharmtech, Inc., together with its subsidiary, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals in Italy, the United States, Japan, Germany, Taiwan, Switzerland, China, and internationally. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofen sodium, methylphenidate HCl, pentobarbital sodium, pimobendan, probucol, propafenone HCI, sodium valproate, thiopental, and valproic acid; and develops benserazide, CBN, and CBD. It also provides intermediate products, such as diethyl isobutyl malonate, benzhydrylamine, 1-Benzhydrylazetidin-3-ol, azetidin-3-ol hydrogenchloride, 1-(2-hydroxyphenyl)-3-phenylpropan-1-one, ritalinic acid, d-ritalinic acid HCl, pyrogallol aldehyde, menthadienol, 5-pentylbenzene-1,3-diol olivetol, methyl 2,4-dihydroxy-6-pentylbenzoate, ethyl 2,4-dihydroxy-6-pentylbenzoate ethyl olivetolate, divarinol, lisdexamfetamine intermediate, UDP-GIcNAz, and UDP-GaINAz. In addition, the company offers customized production services. The company was incorporated in 1987 and is based in Taoyuan City, Taiwan.

Read Less